## Dienst Oncologie

# **ANAL CANCER**


### General Overview

UZA'

- Incidence has increased, particular among women
- Risk factors: Female, HPV infection, smoking, HIV, anal intercourse, multiple sexual partners
- Symptoms: bleeding, rectal mass, asymptomatic
- Lymphatic drainage
  - Above dentate line: mesorectal and internal iliac nodes
  - o Below dentate line: superficial inguinal and external iliac nodes
- ! The anal canal extends from rectum to perianal skin. Tumours of anal margin and perianal skin defined as within 5 cm of the anal margin are now classified with carcinoma of the anal canal!

#### Staging (AJCC Version 9) and Prognosis

- PET-CT, digital rectal examination, anoscopy, palpation regional LN
- For women: screen as well for cervical cancer
- Prognosis:
  - o 50% Localized: 80% 5y survival
  - o 30% Local involvement: 60% 5y survival
  - o 20% distant metastasis: 30% 5y survival



Primary Tumor (T)	Regional Lymph Nodes (N)	Distant Metastasis (M)
<ul> <li>Tx: Primary tumor cannot be assessed</li> <li>T0: No evidence of primary tumor</li> <li>Tis: carcinoma in situ, Bowen, HSIL, AIN II-III</li> <li>T1: Tumor 2cm or less in greatest dimension</li> <li>T2: Tumor &gt; 2 cm but no more than 5 cm in greatest dimension</li> <li>T3: Tumor &gt; 5 cm in greatest dimension</li> <li>T4: Tumor of any size invades adjacent organ(s), eg vagina, urethra, bladder (direct invasion of the rectal wall, perianal skin, SC tissue or the sphincter muscle is not classified as T4)</li> </ul>	Nx: LN cannot be assessed N0: no regional LN N1: metastasis in regional LN N1a: inguinal, mesorectal, superior rectal, internal iliac, obturator lymphnodes N1b: external iliac nodes N1c: N1b with any N1a node	M0: no distant M+ M1: distant M+

- Anatomic Stage (<u>https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21780</u>)
  - Stage I: T1N0M0
  - Stage IIA: T2N0M0
  - Stage IIB: T1-2N1M0
  - Stage IIIA: T3N0-1M0
  - Stage IIIB: T4N0M0
  - Stage IIIC: T4N1M0

Update: September 2024

## Dienst Oncologie



- Local excision in carefully selected patients
- Chemoradiotherapy (with mitomycine / 5-FU) for localized disease (1,2)
- Substitution of capecitabine for 5-FU is acceptable
- Replacement of mitomycin by cisplatin: similar pCR, PFS and OS (3)
- Monitor treatment response:
  - Clinically 8 12 weeks after completion of chemoradiotherapy
  - In case of clinical complete response (CR): re-evaluate 3 6 months with DRE, anuscopy
  - Annual CT thorax/Abdomen for at least 3 years
  - 26 weeks is the optimal time to assess CR if salvage surgery is discussed . Residual tumour should be confirmed histologically (4)
- Treatment of metastatic disease:
  - Cisplatin 5FU in the past standard first line option (60% RR)
  - Carbo/Taxol (InterAACT trial) (5) currently standard because of similar RR but better survival and tolerability
  - No standard second line. Options:
    - FOLFIRI
    - Paclitaxel
    - Cetuximab (KRAS wild type) (no reimbursement or label)
    - Immunotherapy: nivolumab, pembrolizumab (no reimbursement or label)

#### References

- 1) ACT I trial: Lancet 1996 and Northover J et al Br J Cancer 2010
- 2) EORTC trial: JCO 1997;15(5):2040
- 3) ACT II trial: Lancet Oncology 2013
- 4) Lancet oncology feb 2017 (Glynne-Jones R et al)
- 5) JCO 2020 Rao S et al

#### What's new ?

- Phase II with nivolumab 3mg/kg Q2W (Lancet oncology 2017):
  - o 37 patients, 24% RR, PFS 4.1m, mOS 11.5m
- Keynote 028 with pembrolizumab 10 mg/kg Q2W (Annals of oncology 2017):
  - o 25 patients, 17% RR,
- Keynote 158 with pembrolizumab 200 mg Q3W (Lancet Gastroenterol Hepatol 2022)
  - o 112 patients, 11% RR, mOS 11.9m
- PODIUM-303 study (ESMO 2024): phase 3 (Rao S, et al, INTERAACT 2)
  - Retifanlimab (anti-PD1) + carboplatin/paclitaxel superior to chemo alone
  - $\circ$  PFS 9.3 vs 7.4 months. Crossover allowed. OS data immature but trend to better OS
  - In the future probably new standard